ReviewDialogues in clinical neuroscience2007
Neuropsychiatric consequences of cardiovascular medications.
Review in Dialogues in clinical neuroscience, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Unmet challenges in treating hypertension in patients with borderline personality disorder: A systematic review.Medicine · 2019Pooled it
- Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2017Pooled it
- Social Isolation and Daily Steps Are Associated With Fatigue in Older Women With Cardiovascular Disease: A Secondary Analysis of the MindMoves Trial.Journal of aging and physical activity · 2026Trial
- Balance and motor speech impairment in essential tremor.Cerebellum (London, England) · 2009Trial
- Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy.Journal of clinical psychopharmacology · 2009Trial
- Identification of AICD-associated transcriptomic markers in major depressive disorder.Frontiers in psychiatry · 2026Article
- Integrating mental health and cardiovascular wellness: synergistic impacts and the promise of comprehensive care models.Annals of medicine and surgery (2012) · 2025Review
- Access to mental health services for people living with heart failure: a qualitative study.BMJ open · 2025Article
- Neuropsychiatry of atrial fibrillation: dementia and beyond.Frontiers in cardiovascular medicine · 2025Review
- A sex-sensitive LC-MS/MS method with isotopic internal standard for prazosin bioequivalence: bridging precision medicine and generic drug policy in China.Frontiers in pharmacology · 2025Article
- Case Files of the Emory University Medical Toxicology Fellowship: A Patient Presents to the Outpatient Toxicology Clinic with Delusions of Being Poisoned.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2024Article
- Incidence of Postoperative Delirium among Elderly Patients after Elective Surgeries under Anesthesia in the Charity Services of the Philippine General Hospital.Acta medica Philippina · 2024Article
- The Association between Birthweight and Use of Cardiovascular Medications: The Role of Health Behaviors.Journal of cardiovascular development and disease · 2023Article
- Centrally acting antihypertensives and alpha-blockers in people at risk of falls: therapeutic dilemmas-a clinical review.European geriatric medicine · 2023Review
- Heart-brain connections: Phenotypic and genetic insights from magnetic resonance images.Science (New York, N.Y.) · 2023Article
- Heart Rate Variability as a Translational Dynamic Biomarker of Altered Autonomic Function in Health and Psychiatric Disease.Biomedicines · 2023Review
- Associations between β-blockers and psychiatric and behavioural outcomes: A population-based cohort study of 1.4 million individuals in Sweden.PLoS medicine · 2023Article
- New-onset hallucinations with amiodarone: a case report.Annals of general psychiatry · 2022Article
- Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments.Current pain and headache reports · 2022Review
- The association between cardiac drug therapy and anxiety among cardiac patients: results from the national DenHeart survey.BMC cardiovascular disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of cardiovascular medications can have a variety of neuropsychiatric consequences. Many cardiovascular agents cause higher rates of fatigue and sedation than placebo, and case reports of medication-induced mood syndromes, psychosis, and cognitive disturbances exist for many cardiovascular drugs. Depression has been associated with P3-blockers, methyldopa, and reserpine, but more recent syntheses of the data have suggested that these associations are much weaker than originally believed. Though low cholesterol levels have been associated with depression and suicide, lipid-lowering agents have not been associated with these adverse effects. Finally, cardiovascular medications may have beneficial neuropsychiatric consequences; for example, the use of clonidine in patients with attention deficit-hyperactivity disorder, the use of prazosin for patients with post-traumatic stress disorder; and the use of propranolol for performance anxiety and akathisia.
Indexed as
Identifiers
17506224PMC3181843W2163047339What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.